Taldefgrobep alfa

Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2].

Product Specifications

CAS Number

[1580555-26-5]

Product Name Alternative

BMS 986089; RG 6206; RO 7239361; BHV2000

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/taldefgrobep-alfa.html

Purity

98.65

Solubility

10 mM in DMSO

Smiles

[Taldefgrobepalfa]

Molecular Weight

(75.59 kDa)

References & Citations

[1]Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016 Feb;8 (3) :193-204. |[2]Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42 (12) .